Stemcell Transplantation Assisted Reproduction Research Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
- Paid Up Capital ₹ 8.20 Cr
- Company Age 8 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 10.07 Cr
- Revenue Growth -1.89%
- Profit Growth 50.44%
- Ebitda -0.63%
- Net Worth 85.08%
- Total Assets 18.99%
About Stemcell Transplantation Assisted Reproduction Research
Stemcell Transplantation Assisted Reproduction Research Private Limited (STARRPL) is a Private Limited Indian Non-Government Company incorporated in India on 02 March 2016 (Eight years and 11 months 13 days old ). Its registered office is in Tiruchirappalli, Tamil Nadu, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 8.20 Cr.
The company currently has active open charges totaling ₹10.07 Cr.
Govindasamy Rajarathinam and Kalaiselvi Rajarathinam serve as directors at the Company.
Company Details
-
Location
Tiruchirappalli, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U85100TN2016PTC104490
-
Company No.
104490
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
02 Mar 2016
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Stemcell Transplantation Assisted Reproduction Research?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Govindasamy Rajarathinam
|
Whole-Time Director | 02-Mar-2016 | Current |
|
Kalaiselvi Rajarathinam
|
Director | 02-Mar-2016 | Current |
Financial Performance of Stemcell Transplantation Assisted Reproduction Research.
Stemcell Transplantation Assisted Reproduction Research Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 1.89% decrease. The company also saw a substantial improvement in profitability, with a 50.44% increase in profit. The company's net worth Soared by an impressive increase of 85.08%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Stemcell Transplantation Assisted Reproduction Research?
In 2023, Stemcell Transplantation Assisted Reproduction Research had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Kims Ivf Fertility Centre Private LimitedGovindasamy Rajarathinam and Kalaiselvi Rajarathinam are mutual person
Charges (Loans)
₹10.07 Cr
₹0
Charges Breakdown by Lending Institutions
- Canara Bank : 6.60 Cr
- Others : 3.06 Cr
- Bank Of India : 0.41 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Oct 2017 | Bank Of India | ₹4.10 M | Open |
| 27 Sep 2017 | Others | ₹1.74 Cr | Open |
| 30 Jun 2017 | Others | ₹1.32 Cr | Open |
| 02 Mar 2017 | Canara Bank | ₹6.60 Cr | Open |
How Many Employees Work at Stemcell Transplantation Assisted Reproduction Research?
Unlock and access historical data on people associated with Stemcell Transplantation Assisted Reproduction Research, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Stemcell Transplantation Assisted Reproduction Research, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Stemcell Transplantation Assisted Reproduction Research's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.